Chronic rejection had been a black box. Now they have a roadmap.
Por décadas, el rechazo crónico de trasplantes de pulmón fue una sentencia sin explicación: más de la mitad de los receptores perdían el órgano en cinco años, y la medicina solo podía observar sin comprender. Investigadores de Northwestern Medicine han trazado por primera vez el mapa celular y molecular de ese proceso, descubriendo que células estructurales del donante y células inmunes del receptor mantienen un diálogo destructivo que impulsa la cicatrización y el fallo orgánico. Lo que hace aún más significativo este hallazgo es que los mismos actores celulares aparecen en enfermedades pulmonares muy distintas —fibrosis, EPOC, daño por COVID-19—, sugiriendo que comprender una condición podría iluminar el tratamiento de todas las demás.
- Más del 50% de los receptores de trasplante pulmonar pierden el órgano en cinco años, y hasta ahora no existía ningún tratamiento una vez iniciado el rechazo crónico.
- Un equipo de Northwestern Medicine analizó casi 1,6 millones de células de pulmones trasplantados y encontró patrones de comunicación celular anómalos que nadie había podido ver antes.
- Las células estructurales del donante y las inmunes del receptor 'conversan' de forma dañina, acelerando la cicatrización progresiva del órgano en un mecanismo ahora identificado por primera vez.
- Los mismos tipos celulares —KRT17 y KRT5— aparecen también en fibrosis pulmonar idiopática, EPOC, enfermedad pulmonar intersticial y daño pulmonar por COVID-19, abriendo la puerta a tratamientos compartidos entre enfermedades.
- El hallazgo convierte el rechazo crónico de un misterio irresoluble en un problema con mecanismos visibles e interrumpibles, transformando las perspectivas para miles de pacientes trasplantados y muchos más con enfermedades pulmonares fibróticas.
Durante décadas, el rechazo crónico de trasplantes de pulmón fue una realidad que la medicina aceptaba sin poder explicar. Más de la mitad de los receptores veían fallar su nuevo órgano antes de cumplir cinco años, y era la principal causa de muerte pasado el primer año postrasplante. Los médicos observaban el proceso, pero no podían ver su mecanismo. Esa caja negra acaba de abrirse.
Investigadores de Northwestern Medicine analizaron cerca de 1,6 millones de células procedentes de pulmones trasplantados en distintos estadios de enfermedad crónica. Lo que encontraron fue un patrón: tras el trasplante emergen células anómalas que se comunican entre sí de forma destructiva, impulsando el daño progresivo y el rechazo. Era el primer mapa celular y molecular completo de cómo se desarrolla este proceso.
El mecanismo central implica un diálogo perjudicial entre células estructurales del pulmón del donante y células inmunes del receptor. Pero el descubrimiento fue más lejos: los investigadores identificaron tipos celulares específicos —denominados KRT17 y KRT5— que no solo aparecen en el rechazo de trasplantes, sino también en fibrosis pulmonar idiopática, enfermedad pulmonar intersticial, EPOC y daño pulmonar por COVID-19. Los mismos actores celulares impulsan la destrucción en condiciones muy distintas.
El Dr. Ankit Bharat, cirujano torácico y autor principal del estudio, subrayó la implicación más inmediata: al comparar el rechazo crónico con otras enfermedades pulmonares cicatrizantes, el equipo identificó tanto características comunes como únicas. Eso significa que un fármaco desarrollado para pacientes trasplantados podría beneficiar a alguien con fibrosis pulmonar, y viceversa.
En Estados Unidos se realizan entre 3.000 y 3.500 trasplantes de pulmón al año; en todo el mundo, más de 69.000 en total. Sin embargo, la disfunción crónica del aloinjerto sigue siendo intratable una vez que se desarrolla, y el único recurso disponible es un segundo trasplante. Este estudio no promete una cura inmediata, pero transforma el rechazo de misterio irresoluble en problema con mecanismos visibles —y los mecanismos pueden interrumpirse.
More than half of lung transplant recipients watch their new organ fail within five years. For decades, doctors knew this happened—it was the leading cause of death after the first year following transplant—but they couldn't explain why. The body's rejection of a foreign organ seemed inevitable, a biological fact as immutable as gravity. Now researchers at Northwestern Medicine have opened that black box.
The team analyzed nearly 1.6 million cells from transplanted lungs in various states of chronic disease and found something unexpected: a pattern. Abnormal cells emerged after transplantation, and the way they communicated with each other—the cellular conversations happening inside the organ—drove progressive damage and rejection. It was the first complete cellular and molecular map of how lung transplant rejection actually unfolds.
The mechanism turned out to involve a harmful dialogue between two types of cells: structural cells from the donor's lung and immune cells from the recipient's body. These cells were talking to each other in ways that accelerated scarring and organ failure. But the discovery went deeper. The researchers identified specific cell types—labeled KRT17 and KRT5—that appeared not just in transplant rejection but in multiple scarring lung diseases: idiopathic pulmonary fibrosis, interstitial lung disease, COPD, COVID-19 lung damage, and others. The same cellular actors were driving damage across different conditions.
Dr. Ankit Bharat, the study's lead author and a thoracic surgeon at Northwestern's Feinberg School of Medicine, described the significance plainly. Chronic lung transplant rejection had been a mystery—doctors observed it happening but couldn't see the mechanism. Now they had a roadmap. "By comparing chronic rejection with other scarring lung diseases, we identified features that are common and features that are unique," Bharat explained. The implication was profound: treatments developed for one condition might work for another. A drug designed to help transplant patients could potentially help someone with pulmonary fibrosis. The benefits extended far beyond the transplant population.
In the United States alone, surgeons perform between 3,000 and 3,500 lung transplants annually. Globally, more than 69,000 have been completed to date. Yet chronic allograft dysfunction—the medical term for various forms of chronic lung transplant rejection—remains untreatable once it develops. Patients facing this complication have essentially one option: another transplant, if they can get one.
This research opens a different path. By understanding the cellular communication patterns that drive rejection, scientists can now explore new drug targets and therapeutic strategies. The study doesn't promise a cure tomorrow, but it transforms rejection from an unsolved mystery into a problem with visible mechanisms—and mechanisms can be interrupted. For the thousands of people living with transplanted lungs, and for the many more facing scarring lung diseases of other origins, that shift from darkness to understanding changes everything about what comes next.
Citações Notáveis
Chronic lung transplant rejection had been a black box. We knew it occurred, but we didn't know exactly why. Our study provides the first complete cellular and molecular roadmap of the disease.— Dr. Ankit Bharat, Northwestern Medicine
By comparing chronic rejection with other scarring lung diseases, we identified features that are common and features that are unique. This means treatments developed for one condition could help others.— Dr. Ankit Bharat, Northwestern Medicine
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take so long to figure out what was happening inside these lungs?
Because the organ is complex and the rejection happens slowly, over years. You can't just look at a lung and see the cellular conversations. It took new technology to analyze 1.6 million individual cells and map their interactions.
So doctors knew rejection was happening but couldn't see why?
Exactly. They could observe the outcome—the organ failing—but not the mechanism. It's like watching a car break down without being able to open the hood.
What makes this discovery useful beyond transplants?
The same cell types causing rejection appear in fibrosis, COPD, COVID lung damage. If you develop a drug that stops those cells from communicating harmfully in a transplant patient, it might help someone with pulmonary fibrosis too.
Is there a treatment coming soon?
Not immediately. But now that researchers can see the mechanism, they know what to target. That's the real shift—from guessing to having a map.
What happens to transplant patients right now?
If chronic rejection develops, there's no effective treatment. Their only option is another transplant, if they can get one. This research could change that.
How many people are we talking about?
In the U.S., thousands of transplants happen each year. More than half of recipients will experience rejection within five years. Globally, it's the leading cause of death after the first year post-transplant.